nach oben

Erschienen in:

06.11.2019 | PRECLINICAL STUDIES

7-Chloroquinoline-1,2,3-triazoyl carboxamides induce cell cycle arrest and apoptosis in human bladder carcinoma cells

verfasst von: Mariana S. Sonego, Natália V. Segatto, Lucas Damé, Mariana Fronza, Carolina B. Gomes, Thais Larré Oliveira, Fabiana Kömmling Seixas, Lucielli Savegnago, Kyle M. Schachtschneider, Diego Alves, Tiago Collares

Erschienen in: Investigational New Drugs | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Summary

In the present study, the antitumoral properties of a series of 7-chloroquinoline-1,2,3-triazoyl-carboxamides (QTCA) were investigated by analyzing their cytotoxic activities against human bladder cells (5637; grade II carcinoma). In addition, their effects on cell viability, cell cycle arrest mechanisms, apoptosis induction, in silico molecular docking, and detection of pro-apoptotic and anti-apoptotic proteins were evaluated. The cytotoxicity assay identified major dose- and time-dependent cytotoxic effects in 5637 cells after they were exposed to treatment with QTCA, only minimal effects were observed on normal cells. A live/dead assay confirmed that significant cell death, arrest in the G0/G1 phase and apoptosis were associated with treatment by 1-(7-Chloroquinolin-4-yl)-5-methyl-N-phenyl-1H-1,2,3-triazole-4-carboxamide (QTCA-1) and 1-(7-Chloroquinolin-4-yl)-N-(4-fluorophenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamide (QTCA-4). The in silico results indicated that these compounds acted through different mechanisms for the induction of cell cycle arrest and apoptosis. Western blotting confirmed the binding of the QTCAs to pro- and anti-apoptotic proteins. In conclusion, QTCA-1 and QTCA-4 are promising candidates for inducing cytotoxicity, cell cycle arrest, and apoptosis in human bladder cancer cells.

Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. 67:7–30. https://doi.org/10.3322/caac.21387

American Cancer Society (2018) Cancer Facts & Figures 2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf

Yeung C, Dinh T, Lee J (2014) The health economics of bladder Cancer: an updated review of the published literature. Pharmacoeconomics 32:1093–1104. https://doi.org/10.1007/s40273-014-0194-2 CrossRefPubMed

Eifler JB, Scarpato KR, Clark PE (2015) Management of noninvasive bladder cancers. Curr Opin Oncol 27:185–190. https://doi.org/10.1097/CCO.0000000000000173 CrossRefPubMed

Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y (2017) Bladder cancer. Nat Rev Dis Prim:31–19. https://doi.org/10.1038/nrdp.2017.22

Su H, Jiang H, Tao T, Kang X, Zhang X, Kang D, Li S, Li C, Wang H, Yang Z, Zhang J, Li C (2019) Hope and challenge: precision medicine in bladder cancer. Cancer Med 8:1806–1816. https://doi.org/10.1002/cam4.1979 CrossRefPubMedPubMedCentral

Tomaszewski JJ, Smaldone MC (2010) Emerging intravesical therapies for management of nonmuscle invasive bladder cancer. Open Access J Urol 2:67–84PubMedPubMedCentral

Logan C, Brown M, Hayne D (2012) Intravesical therapies for bladder cancer – indications and limitations. BJU Int 110:12–21. https://doi.org/10.1111/j.1464-410X.2012.11619.x CrossRefPubMed

Grossman HB, O’donnell MA, Cookson MS, Greenberg RE, Keane TE (2008) Bacillus calmette-guerin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev Urol 10(4):281–289PubMedPubMedCentral

10.

Pfeffer CM, Singh ATK (2018) Apoptosis: a target for anticancer therapy. Int J Mol Sci 19(2):448. https://doi.org/10.3390/ijms19020448 CrossRefPubMedCentral

11.

Lednicer D (2007) The organic chemistry of drug synthesis. Wiley 7. https://doi.org/10.1002/9780470180679

12.

Kumar S, Bawa S, Gupta H (2009) Biological activities of Quinoline derivatives. Mini-Reviews Med Chem 9:1648–1654. https://doi.org/10.2174/138955709791012247 CrossRef

13.

Wilhelm EA, Machado NC, Pedroso AB, Goldani BS, Seus N, Moura S, Savegnago L, Jacob RG, Alves D (2014) Organocatalytic synthesis and evaluation of 7-chloroquinoline-1,2,3-triazoyl carboxamides as potential antinociceptive, anti-inflammatory and anticonvulsant agent. RSC Adv 4:41437–41445. https://doi.org/10.1039/C4RA07002J CrossRef

14.

Manera C, Cascio MG, Benetti V, Allarà M, Tuccinardi T, Martinelli A, Saccomanni G, Vivoli E, Ghelardini C, Di Marzo V, Ferrarini PL (2007) New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg Med Chem Lett 17:6505–6510. https://doi.org/10.1016/j.bmcl.2007.09.089 CrossRefPubMed

15.

Dorey G, Lockhart B, Lestage P, Casara P (2000) New quinolinic derivatives as centrally active antioxidants. Bioorg Med Chem Lett 10:935–939. https://doi.org/10.1016/S0960-894X(00)00122-0 CrossRefPubMed

16.

Saraiva MT, Krüger R, Baldinotti RSM, Lenardão EJ, Luchese C, Savegnago L, Wilhelm EA, Alves D (2016) 7-chloroquinoline-1,2,3-triazoyl carboxylates: Organocatalytic synthesis and antioxidant properties. J Braz Chem Soc 27:41–53. https://doi.org/10.5935/0103-5053.20150239 CrossRef

17.

Naik HRP, Naik HSB, Naik TRR, Naika HR, Gouthamchandra K, Mahmood R, Ahamed BMK (2009) Synthesis of novel benzo[h]quinolines: wound healing, antibacterial, DNA binding and in vitro antioxidant activity. Eur J Med Chem 44:981–989. https://doi.org/10.1016/j.ejmech.2008.07.006 CrossRefPubMed

18.

Nayyar A, Malde A, Coutinho E, Jain R (2006) Synthesis, anti-tuberculosis activity, and 3D-QSAR study of ring-substituted-2/4-quinolinecarbaldehyde derivatives. Bioorg Med Chem 14:7302–7310. https://doi.org/10.1016/j.bmc.2006.06.049 CrossRefPubMed

19.

Bawa S, Kumar S, Drabu S, Kumar R (2010) Structural modifications of quinoline-based antimalarial agents: recent developments. J Pharm Bioallie Sci 2:64. https://doi.org/10.4103/0975-7406.67002 CrossRef

20.

Clemence F, Le Martret O, Delevallee F, Benzoni J, Jouanen A, Jouquey S, Mouren M, Deraedt R (1988) 4-hydroxy-3-quinolinecarboxamides with Antiarthritic and analgesic activities. J Med Chem 31:1453–1462. https://doi.org/10.1021/jm00402a034 CrossRefPubMed

21.

Wallace OB, Lauwers KS, Jones SA, Dodge JA (2003) Tetrahydroquinoline-based selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett 13:1907–1910. https://doi.org/10.1016/S0960-894X(03)00306-8 CrossRefPubMed

22.

Begnini KR, Duarte WR, da Silva LP, Buss JH, Goldani BS, Fronza M, Segatto NV, Alves D, Savegnago L, Seixas FK, Collares T (2017) Apoptosis induction by 7-chloroquinoline-1,2,3-triazoyl carboxamides in triple negative breast cancer cells. Biomed Pharmacother 91:510–516. https://doi.org/10.1016/j.biopha.2017.04.098 CrossRefPubMed

23.

Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AI, Sim GA (1966) Plant antitumor agents. I. the isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate. J Am Chem Soc 88:3888–3890CrossRef

24.

Ulukan H, Swaan PW (2002) Camptothecins, a review of their chemotherapeutical potential. Drugs 62:2039–2057. https://doi.org/10.1016/j.ejmech.2013.01.058 CrossRefPubMed

25.

Melo JOF, Donnici CL, Augusti R, Ferreira VF, De Souza MCBV, Ferreira MLG, Cunha AC (2006) Heterociclos 1,2,3-triazólicos: Histórico, métodos de preparação, aplicações e atividades farmacológicas. Quim Nova 29:569–579. https://doi.org/10.1590/S0100-40422006000300028 CrossRef

26.

Thomas KD, Adhikari AV, Shetty NS (2010) Design, synthesis and antimicrobial activities of some new quinoline derivatives carrying 1,2,3-triazole moiety. Eur J Med Chem 45:3803–3810. https://doi.org/10.1016/j.ejmech.2010.05.030 CrossRefPubMed

27.

Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63. https://doi.org/10.1016/0022-1759(83)90303-4 CrossRefPubMed

28.

Ferrari M, Fornasiero MC, Isetta AM (1990) MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J Immunol Methods 131:165–172. https://doi.org/10.1016/0022-1759(90)90187-Z CrossRefPubMed

29.

Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR (2012) Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. Aust J Chem 4(1):17. https://doi.org/10.1186/1758-2946-4-17 CrossRef

30.

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS et al (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785–2791. https://doi.org/10.1002/jcc.21256 CrossRefPubMedPubMedCentral

31.

Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC et al (2004) UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem United States 25(13):1605–1612. https://doi.org/10.1002/jcc.20084 CrossRef

32.

Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 31:455–461. https://doi.org/10.1002/jcc.21334 CrossRefPubMedPubMedCentral

33.

Böhm HJ, Banner D, Bendels S, Kansy M, Kuhn B, Müller K, Obst-Sander U, Stahl M (2004) Fluorine in medicinal chemistry. Chem Bio Chem 5:637–643. https://doi.org/10.1002/cbic.200301023 CrossRefPubMed

34.

O’Hagan D (2010) Fluorine in health care: Organofluorine containing blockbuster drugs. J Fluor Chem 131:1071–1081. https://doi.org/10.1016/j.jfluchem.2010.03.003 CrossRef

35.

Afzal O, Kumar S, Haider R, Ali R, Kumar R, Jaggi M, Bawa S (2014) A review on anticancer potential of bioactive heterocycle quinolone. Eur J Med Chem:1–40. https://doi.org/10.1016/j.ejmech.2014.07.044

36.

Munchen TS, Sonego MS, De Souza D, Dornelles L, Seixas FK, Collares T, Piccoli BC, D’Avila da Silva F, da Rocha JBT, Quoos N, Rodrigues OED (2018) New 3′ -Triazolyl-5′-aryl-chalcogenothymidine: synthesis and anti-oxidant and Antiproliferative bladder carcinoma (5637) activity. Chemistry Select 3:3479–3486. https://doi.org/10.1002/slct.201800156 CrossRef

37.

Wagner MS, Shultze E, Oliveira TL, De Leon PM, Campos VF, Oliveira I, Souza D, Rodrigues OED, Collares T, Seixas FK (2018) Revitalizing the AZT through of the selenium:na approach in human triple negative breast cancer cell line. Front Oncol (8):525. https://doi.org/10.3389/fonc.2018.00525

38.

Sena-Lopes A, Bezerra FSB, das Neves RN, De Pinho RB, De Oliveira Silva MT, Savegnago L, Collares T, Seixas F, Begnini K, JAP H, Ely MR, Rufatto LC, Moura S, Barcellos T, Padilha F, Dellagostin O, Borsuk S (2018) Chemical composition, immunostimulatory, cytotoxic and antiparasitic activities of the essential oil from Brazilian red propolis. PLoS One 13(2):1–16. https://doi.org/10.1371/journal.pone.0191797 CrossRef

39.

Ooi KK, Yeo CI, Mahandaran T et al (2017) G2/M cell cycle arrest on HT-29 cancer cells and toxicity assessment of triphenylphosphanegold(I) carbonimidothioates, Ph3PAu[SC(OR)=NPh], R=me, et, and iPr, during zebrafish development. J Inorg Biochem 166:173–181. https://doi.org/10.1016/j.jinorgbio.2016.11.008 CrossRefPubMed

40.

Sri Ramya PV, Guntuku L, Angapelly S, Karri S, Digwal CS, Babu BN, Naidu VGM, Kamal A (2018) Curcumin inspired 2-chloro/phenoxy quinoline analogues: synthesis and biological evaluation as potential anticancer agents. Bioorg Med Chem Lett 28(5):892–898. https://doi.org/10.1016/j.bmcl.2018.01.070 CrossRefPubMed

41.

Rubin E & Farber JL (1999) Neoplasia. In Rubin, E.; Farber, J.L. Pathology. 3 ed. Philadelphia: Lippincott Raven 155–21

42.

Nicholson DW (2000) From bench to clinic with apoptosis-based therapeutic agents. Nature 407:810–816. https://doi.org/10.1038/35037747 CrossRefPubMed

43.

Taylor RC, Cullen SP, Martin SJ (2008) Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9:231–241. https://doi.org/10.1038/nrm2312 CrossRefPubMed

44.

Lauber K, Blumenthal SG, Waibel M, Wesselborg S (2004) Clearance of apoptotic cells: getting rid of the corpses. Mol Cell 14:277–287. https://doi.org/10.1016/S1097-2765(04)00237-0 CrossRefPubMed

45.

Li SY, Chen YL, Wang C, Tzeng CC (2006) Synthesis and antiproliferative evaluation of certain pyrido[3,2-g]quinoline derivatives. Bioorg Med Chem 14:7370–7376. https://doi.org/10.1016/j.bmc.2006.07.030 CrossRefPubMed

46.

Carneiro MLB, Porfírio EP, Otake AH, Chammas R, Báo SN, Guillo LA (2010) Morphological alterations and G0/G1 cell cycle arrest induced by Curcumin in human SK-MEL-37 melanoma cells. Braz Arch Biol Technol 53(2):343–352 ISSN 1516-8913CrossRef

47.

Zhang Y, Li Z, Min Q, Palida A, Zhang Y, Tang R et al (2018) 8-Chrysoeriol, as a potential BCL-2 inhibitor triggers apoptosis of SW1990 pancreatic cancer cells. Bioorg Chem United States 77:478–484. https://doi.org/10.1016/j.bioorg.2018.01.042 CrossRef

48.

Chandrashekhar R, Ram B, Bhavani NL, Bakshi V (2017) Molecular docking studies of Hydrazide-Hydrazone derivatives of gossypol against Bcl-2 family anti-apoptotic targets. Drug Des 6:155. https://doi.org/10.4172/2169-0138.1000155 CrossRef

49.

Ding J, Mooers BHM, Zhang Z, Kale J, Falcone D, McNichol J et al (2014) After embedding in membranes antiapoptotic Bcl-XL protein binds both Bcl-2 homology region 3 and helix 1 of proapoptotic Bax protein to inhibit apoptotic mitochondrial permeabilization. J Biol Chem 289(17):11873–11896. https://doi.org/10.1074/jbc.M114.552562 CrossRefPubMedPubMedCentral

50.

Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49:223–241. https://doi.org/10.1146/annurev.pharmtox.48.113006.094723 CrossRefPubMedPubMedCentral

51.

Neochoritis CG, Wang K, Estrada-Ortiz N, Herdtweck E, Kubica K, Twarda A, Zak KM, Holak TA, Dömling A (2015) 2,3′-Bis(1′H-indole) heterocycles: new p53/MDM2/MDMX antagonists. Bioorg Med Chem Lett 25:5661–5666. https://doi.org/10.1016/j.bmcl.2015.11.019 CrossRefPubMedPubMedCentral

52.

Atatreh N, Ghattas MA, Bardaweel SK, Rawashdeh SAL, Sorkhy MAL (2018) Identification of new inhibitors of Mdm2 – p53 interaction via pharmacophore and structure- based virtual screening. Drug Des Devel Ther 12:3741–3752. https://doi.org/10.2147/DDDT.S182444 CrossRefPubMedPubMedCentral

53.

Song X, Xiong Y, Qi X, Tang W, Dai J, Gu Q et al (2018) Molecular targets of active anticancer compounds derived from marine sources. Mar Drugs Switzerland 16(5):175. https://doi.org/10.3390/md16050175 CrossRef

54.

Estrada-Ortiz N, Neochoritis CG, Domling A (2016) How to design a successful p53-MDM2/X interaction inhibitor: a thorough overview based on crystal structures. Chem Med Chem Germany 11(8):757–772. https://doi.org/10.1002/cmdc.201500487 CrossRef

55.

Campbell KJ, Tait SWG (2018) Targeting BCL-2 regulated apoptosis in cancer. Open Biol 8(5):1–11. https://doi.org/10.1098/rsob.180002 CrossRef

56.

Yip KW, Reed JC (2008) Bcl-2 family proteins and cancer. Oncogene 27:6398–6406. https://doi.org/10.1038/onc.2008.307 CrossRefPubMed

57.

Elkholi R, Renault TT, Serasinghe MN, Chipuk JE (2014) Putting the pieces together: how is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy? Cancer Metab 2:16. https://doi.org/10.1186/2049-3002-2-16 CrossRefPubMedPubMedCentral

Titel: 7-Chloroquinoline-1,2,3-triazoyl carboxamides induce cell cycle arrest and apoptosis in human bladder carcinoma cells
verfasst von: Mariana S. Sonego
Natália V. Segatto
Lucas Damé
Mariana Fronza
Carolina B. Gomes
Thais Larré Oliveira
Fabiana Kömmling Seixas
Lucielli Savegnago
Kyle M. Schachtschneider
Diego Alves
Tiago Collares
Publikationsdatum: 06.11.2019
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 4/2020
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-019-00861-w

A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors

PHASE I STUDIES

A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer

PHASE I STUDIES

Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells

PRECLINICAL STUDIES

Synthesis and cellular effects of novel 1,3,5-triazine derivatives in DLD and Ht-29 human colon cancer cell lines

Open Access
PRECLINICAL STUDIES

Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)

PHASE I STUDIES

Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3

PRECLINICAL STUDIES

Neu im Fachgebiet Onkologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

16.01.2025
Zöliakie
Nachrichten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

15.01.2025
Urothelkarzinom
Nachrichten

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

15.01.2025
Melanom
Nachrichten

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

7-Chloroquinoline-1,2,3-triazoyl carboxamides induce cell cycle arrest and apoptosis in human bladder carcinoma cells

Summary

Weitere Artikel der Ausgabe 4/2020

A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors

A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer

Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells

Synthesis and cellular effects of novel 1,3,5-triazine derivatives in DLD and Ht-29 human colon cancer cell lines

Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)

Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3

Neu im Fachgebiet Onkologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

Update Onkologie

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten